UAE – The Abu Dhabi Department of Health (DoH) and France’s Sanofi, a global healthcare leader, have signed a Declaration of Collaboration to join forces in four strategic healthcare areas.
Signed in Boston as part of the Abu Dhabi Life Science Mission to US, the DoH and Sanofi seek to collaborate in four strategic healthcare priorities including hematology and oncology, rare metabolic diseases, diabetes management and vaccines.
Key activities of the agreement include the cooperation to launch a clinical research project and patient recruitment protocol.
In relation to hematology and oncology, DoH and Sanofi agreed to pursue the creation of data generation and population research projects for late-stage breast cancer, liquid tumors and blood disorders.
Sanofi will support in the launch of a clinical research project and patient recruitment protocol as well as participate in DoH’s Cancer Advisory Group to develop policies significant to the elderly cancer-patient community.
Furthermore, both organizations will cocreate a high-risk population screening project that will support in the detection of rare metabolic diseases utilizing Artificial Intelligence (AI) tools.
Key activities of the agreement include the cooperation to launch a clinical research project and patient recruitment protocol.
In line with Abu Dhabi’s ongoing efforts to achieve a healthier population, both parties will cooperate to integrate the digital healthcare solutions, including “MyStar Space,” into Abu Dhabi healthcare facilities, and study the outcomes and impact of Type II diabetes management.
While Abu Dhabi continues to launch initiatives that educate the mass population on significant healthcare topics, DoH will utilize study findings for the education of patients and healthcare providers.
Supply chain Academy
Additionally, the collaboration will witness the launch of the Supply Chain Academy, an initiative intended to provide and enhance knowledge related to vaccines supply chain, which will be led by an International Federation of Purchasing and Supply Management (IFPSM) certified entity.
The collaboration reaffirms Abu Dhabi’s ongoing efforts to position itself as a premier life science destination and innovation hub.
Dr. Asma Al Mannaei, Executive Director, DoH Research and Innovation Centre, and Jean-Paul Scheuer, MCO Lead & General Manager for Specialty Care at Sanofi in Greater Gulf signed the Declaration of Collaboration.
As part of the Abu Dhabi Life Science Mission, a high-profile Abu Dhabi delegation are in the United States of America to explore opportunities for joint collaboration in the context of healthcare in general and life science in particular.
The visit aims to establish long-term mechanisms that empower the healthcare sector in both countries while also highlighting Abu Dhabi’s distinguished healthcare ecosystem.
The Abu Dhabi delegation to the US witnessed the participation of ten key entities in the life science ecosystem in Abu Dhabi including the Department of Health – Abu Dhabi (DoH), and Abu Dhabi Investment Office (ADIO).
Other entities include Mubadala Health, G42 Healthcare, Abu Dhabi Ports, ADQ, Etihad Cargo, Khalifa University, Hayat-vax and Pure Health.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
